tbuckley/cabot-search huggingface dataset:
Radiographic diagnosis of periodontal diseases – Current evidence versus innovations
Authors: Reinhilde Jacobs, Rocharles Cavalcante Fontenele, Pierre Lahoud, Sohaib Shujaat, Michael M. Bornstein
Journal: Periodontology 2000 (2024)

Accurate diagnosis of periodontal and peri-implant diseases relies significantly on radiographic examination, especially for assessing alveolar bone levels, bone defect morphology, and bone quality. This narrative review aimed to comprehensively outline the current state-of-the-art in radiographic diagnosis of alveolar bone diseases, covering both two-dimensional (2D) and three-dimensional (3D) modalities. Additionally, this review explores recent technological advances in periodontal imaging diagnosis, focusing on their potential integration into clinical practice. Clinical probing and intraoral radiography, while crucial, encounter limitations in effectively assessing complex periodontal bone defects. Recognizing these challenges, 3D imaging modalities, such as cone beam computed tomography (CBCT), have been explored for a more comprehensive understanding of periodontal structures. The significance of the radiographic assessment approach is evidenced by its ability to offer an objective and standardized means of evaluating hard tissues, reducing variability associated with manual clinical measurements and contributing to a more precise diagnosis of periodontal health. However, clinicians should be aware of challenges related to CBCT imaging assessment, including beam-hardening artifacts generated by the high-density materials present in the field of view, which might affect image quality. Integration of digital technologies, such as artificial intelligence-based tools in intraoral radiography software, the enhances the diagnostic process. The overarching recommendation is a judicious combination of CBCT and digital intraoral radiography for enhanced periodontal bone assessment. Therefore, it is crucial for clinicians to weigh the benefits against the risks associated with higher radiation exposure on a case-by-case basis, prioritizing patient safety and treatment outcomes.
Efficacy and safety of second-line treatment with surufatinib for anlotinib-resistant radioiodine-refractory differentiated thyroid cancer: An exploratory multicenter study.
Authors: Yang Wang, Zhongling Qiu, Xufu Wang, Na Han, Jiao Li, Hongyan Zhai, Zhenhu Zhou, Rui Gao, Ting Ji, Libo Chen
Journal: Journal of Clinical Oncology (2024)

e15127 Background: Radioiodine-refractory differentiated thyroid cancer (RR-DTC) resistant to first-line targeted therapy typically exhibits rapidly progressive nature, lacking standard treatment options. This study aimed to assess the efficacy and safety of surufatinib, targeting vascular endothelial growth factor receptor 1/2/3, fibroblast growth factor receptor 1, and colony-stimulating factor-1 receptor, in RR-DTC patients who had failed anlotinib treatment. Methods: This multicenter study enrolled patients aged ≥ 18 years with at least one measurable RR-DTC lesion (RECIST 1.1), who had previously received anlotinib treatment and experienced disease progression. Primary endpoint was progression-free survival (PFS); secondary endpoints were disease control rate and safety. Results: As of December 25, 2023, 9 patients were enrolled. Median age, 56 (range, 29-69) years; Male, 88.9%; ECOG PS 0, 88.9%; papillary carcinoma/follicular carcinoma, 77.8%/22.2%. Lung (77.8%) and bone (33.3%) were the most frequently involved organs. The duration of anlotinib treatment ≤ 12 months was found in 44.4% patients. All the 9 patients underwent at least one efficacy evaluation with a median PFS of 6.3 months and disease control rate of 88.9%. Subsequent analysis revealed that median PFS extended to 9.20 months in patients younger than 56 years, compared to 5.95 months in older individuals. Patients with over 12 months of prior anlotinib treatment exhibited mPFS of 9.20 months, versus 6.25 months in those with shorter prior treatment durations. Common treatment-emergent adverse events observed were hypertension (44.4%), proteinuria (22.2%), decreased platelets (22.2%), fatigue (11.1%), and hemoptysis (11.1%). Grade 3 adverse events included proteinuria (11.1%), fatigue (11.1%), and hemoptysis (11.1%). Conclusions: In patients with anlotinib-resistant RR-DTC, second-line surufatinib treatment yielded promising efficacy and tolerable toxicity, warranting randomized controlled studies on RR-DTC refractory to first-line targeted therapy. Clinical trial information: ChiCTR2100052020 .
Systemic assessment of manual circular stapler versus powered circular stapler for anastomosis in rectal cancer: A multicenter prospective cohort study.
Authors: Xinxiang Li, Yikuan Chen, Ruijia Zhang, Dakui Luo, Fangqi Liu
Journal: Journal of Clinical Oncology (2024)

e15614 Background: Mechanical anastomosis offers several advantages over traditional hand-sutured anastomosis. However, complications such as anastomotic leaks, strictures, and bleeding persist due to factors like interactions between staples and tissue. Powered circular anastomosis is an effective method to address these issues. Currently, there are no domestic studies on the application of powered-anastomosis technology in colorectal anastomosis. Methods: The study adopted a multicenter, randomized, parallel-controlled, non-inferiority study design, with a 1:1 random allocation ratio. The study involved 187 patients with rectal cancer who underwent Dixon surgery using IntoCare™ disposable powered circular stapler (ICS), and 195 patients who received similar process with manual circular stapler (MCS). The efficacy of stapler was evaluated by anastomosis success rate, anastomosis-related adverse events, anastomosis device performance assessment, operation time, anastomosis time, and postoperative recovery. Safety evaluation indicators included adverse events, vital signs, and laboratory tests. Results: Baseline demographic characteristics showed no notable disparities between two groups (Table 1). A high proportion of patients, 99.47% in the MCS group and 99.49% in the ICS group, successfully completed anastomosis. In the MCS group, the average anastomosis duration was clocked at 2.84 minutes (min) (±2.3), with a median time of 2.0 min (ranging from 1.0 to 22.0 min). In contrast, the ICS group exhibited a slightly quicker average anastomosis duration of 2.40 min (±1.7), and a comparable median time of 2.0 min (but with a narrower range from 1.0 to 15.0 min). Adverse events did not differ significantly between two groups. Conclusions: The results uncovered the powered stapler could considerably reduce stapling time while maintaining a safety profile. Notably, the incidence of patients with anastomotic leakage one month post-surgery, and anastomotic stricture six months post-surgery in the powered stapler group, was lower than those in the manual stapler group. This suggests that the anastomosis created by the powered stapler is more stable and promotes more effective postoperative anastomotic healing. Clinical trial information: NCT05879172 . [Table: see text]
Conventional diagnostic criteria for periodontal diseases (plaque‐induced gingivitis and periodontitis)
Authors: Lisa J. A. Heitz‐Mayfield
Journal: Periodontology 2000 (2024)

This narrative review addresses conventional diagnostic criteria used in clinical practice to discriminate between periodontal health, gingivitis, and periodontitis. Visual examination of the color and texture of the periodontal tissues, assessment of plaque deposits, periodontal probing assessments, and diagnostic imaging enable the collation of information to make a periodontal diagnosis, followed by an appropriate treatment plan. The periodontal probe is an essential diagnostic tool to assess probing pocket depth, clinical attachment level, bleeding on probing, and the degree of furcation involvement at multirooted teeth. When clinical signs and symptoms of periodontitis are identified, diagnostic imaging enables evaluation of the level and extent of bone destruction and bone defect morphology. The diagnostic process requires clinicians who are trained to evaluate, record, and interpret these measures. This narrative review focuses on conventional clinical diagnostic parameters which, despite their limitations, are considered the current standard of care.
Testing Quantitative and Qualitative Sex Effects in a National Swedish Twin-Sibling Study of Posttraumatic Stress Disorder
Authors: Ananda B. Amstadter, Sara L. Lönn, Shannon Cusack, Jan Sundquist, Kenneth S. Kendler, Kristina Sundquist
Journal: American Journal of Psychiatry (2024)

Twin studies have demonstrated that posttraumatic stress disorder (PTSD) is moderately heritable, and the pattern of findings across studies suggests higher heritability in females compared with males. Formal testing of sex differences has yet to be done in twin studies of PTSD. The authors sought to estimate the genetic and environmental contributions to PTSD, and to formally test for sex differences, in the largest sample to date of both sexes, among twins and siblings.
Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial
Authors: Alastair J.S. Webb, Jacqueline S. Birks, Karolina A. Feakins, Amy Lawson, Jesse Dawson, Alexander M.K. Rothman, David J. Werring, Osian Llwyd, Catriona R. Stewart, James Thomas
Journal: Circulation Research (2024)

BACKGROUND: Vascular cognitive impairment due to cerebral small vessel disease is associated with cerebral pulsatility, white matter hypoperfusion, and reduced cerebrovascular reactivity (CVR), and is potentially improved by endothelium-targeted drugs such as cilostazol. Whether sildenafil, a phosphodiesterase-5 inhibitor, improves cerebrovascular dysfunction is unknown. METHODS: OxHARP trial (Oxford Haemodynamic Adaptation to Reduce Pulsatility) was a double-blind, randomized, placebo-controlled, 3-way crossover trial after nonembolic cerebrovascular events with mild-moderate white matter hyperintensities (WMH), the most prevalent manifestation of cerebral small vessel disease. The primary outcome assessed the superiority of 3 weeks of sildenafil 50 mg thrice daily versus placebo (mixed-effect linear models) on middle cerebral artery pulsatility, derived from peak systolic and end-diastolic velocities (transcranial ultrasound), with noninferiority to cilostazol 100 mg twice daily. Secondary end points included the following: cerebrovascular reactivity during inhalation of air, 4% and 6% CO 2 on transcranial ultrasound (transcranial ultrasound-CVR); blood oxygen-level dependent–magnetic resonance imaging within WMH (CVR-WMH) and normal-appearing white matter (CVR-normal-appearing white matter); cerebral perfusion by arterial spin labeling (magnetic resonance imaging pseudocontinuous arterial spin labeling); and resistance by cerebrovascular conductance. Adverse effects were compared by Cochran Q. RESULTS: In 65/75 (87%) patients (median, 70 years;79% male) with valid primary outcome data, cerebral pulsatility was unchanged on sildenafil versus placebo (0.02, −0.01 to 0.05; P =0.18), or versus cilostazol (−0.01, −0.04 to 0.02; P =0.36), despite increased blood flow (∆ peak systolic velocity, 6.3 cm/s, 3.5–9.07; P &lt;0.001; ∆ end-diastolic velocity, 1.98, 0.66–3.29; P =0.004). Secondary outcomes improved on sildenafil versus placebo for CVR-transcranial ultrasound (0.83 cm/s per mm Hg, 0.23–1.42; P =0.007), CVR-WMH (0.07, 0–0.14; P =0.043), CVR-normal-appearing white matter (0.06, 0.00–0.12; P =0.048), perfusion (WMH: 1.82 mL/100 g per minute, 0.5–3.15; P =0.008; and normal-appearing white matter, 2.12, 0.66–3.6; P =0.006) and cerebrovascular resistance (sildenafil-placebo: 0.08, 0.05–0.10; P =4.9×10 −8 ; cilostazol-placebo, 0.06, 0.03–0.09; P =5.1×10 −5 ). Both drugs increased headaches ( P =1.1×10 −4 ), while cilostazol increased moderate-severe diarrhea ( P =0.013). CONCLUSIONS: Sildenafil did not reduce pulsatility but increased cerebrovascular reactivity and perfusion. Sildenafil merits further study to determine whether it prevents the clinical sequelae of small vessel disease. REGISTRATION: URL: https://www.clinicaltrials.gov/study/NCT03855332 ; Unique identifier: NCT03855332.
Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3’ by M. P. Goetz et al.
Authors: A.D. Sherry, T.A. Lin, Z.R. McCaw, E.B. Ludmir
Journal: Annals of Oncology (2024)
Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis
Authors: Donia Bahloul, Richard Hudson, Orsolya Balogh, Elgan Mathias, Ben Heywood, Ellen Hubbuck, Onyinye Diribe, Robert McDonald, Anthony Bewley
Journal: British Journal of Dermatology (2024)

Abstract Background Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England. Objectives To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England. Methods This retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged ≥ 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and ≥ 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed. Results A total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P &amp;lt; 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P &amp;lt; 0.001) in patients with MSPN compared with those with MiPN. Conclusions The epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN.
Cardiomyocyte βII spectrin plays a critical role in maintaining cardiac function by regulating mitochondrial respiratory function
Authors: Rongjin Yang, Banjun Ruan, Rutao Wang, Xiaomeng Zhang, Pingping Xing, Congye Li, Yunyun Zhang, Xiaoqian Chang, Haifeng Song, Shun Zhang, Huishou Zhao, Feiyu Zhang, Tao Yin, Tingting Qi, Wenjun Yan, Fuyang Zhang, Guangyu Hu, Shan Wang, Ling Tao
Journal: Cardiovascular Research (2024)

Abstract Aims βII spectrin is a cytoskeletal protein known to be tightly linked to heart development and cardiovascular electrophysiology. However, the roles of βII spectrin in cardiac contractile function and pathological post-myocardial infarction remodelling remain unclear. Here, we investigated whether and how βII spectrin, the most common isoform of non-erythrocytic spectrin in cardiomyocytes, is involved in cardiac contractile function and ischaemia/reperfusion (I/R) injury. Methods and results We observed that the levels of serum βII spectrin breakdown products (βII SBDPs) were significantly increased in patients with acute myocardial infarction (AMI). Concordantly, βII spectrin was degraded into βII SBDPs by calpain in mouse hearts after I/R injury. Using tamoxifen-inducible cardiac-specific βII spectrin knockout mice, we found that deletion of βII spectrin in the adult heart resulted in spontaneous development of cardiac contractile dysfunction, cardiac hypertrophy, and fibrosis at 5 weeks after tamoxifen treatment. Moreover, at 1 week after tamoxifen treatment, although spontaneous cardiac dysfunction in cardiac-specific βII spectrin knockout mice had not developed, deletion of βII spectrin in the heart exacerbated I/R-induced cardiomyocyte death and heart failure. Furthermore, restoration of βII spectrin expression via adenoviral small activating RNA (saRNA) delivery into the heart reduced I/R injury. Immunoprecipitation coupled with mass spectrometry (IP–LC–MS/MS) analyses and functional studies revealed that βII spectrin is indispensable for mitochondrial complex I activity and respiratory function. Mechanistically, βII spectrin promotes translocation of NADH:ubiquinone oxidoreductase 75-kDa Fe-S protein 1 (NDUFS1) from the cytosol to mitochondria by crosslinking with actin filaments (F-actin) to maintain F-actin stability. Conclusion βII spectrin is an essential cytoskeletal element for preserving mitochondrial homeostasis and cardiac function. Defects in βII spectrin exacerbate cardiac I/R injury.
A GWAS in Swedish colorectal cancer families with gastric and prostate cancer.
Authors: Johanna Samola Winnberg, Litika Vermani, Wen Liu, Veronika Soller, Jessada Thutkawkorapin, Mats Lindblad, Annika Lindblom
Journal: Journal of Clinical Oncology (2024)

e15644 Background: We have previously suggested a syndrome with increased risk for colorectal- and other cancers, primarily gastric- and prostate cancer. The data favoured this syndrome inherited as a complex disease. Therefore, we conducted a Genome Wide Association Study (GWAS) on colorectal cancer patients, who’s relatives had prostate-, and/or gastric cancer. Methods: The GWAS analysis consisted of 685 cases of colorectal cancer and 4780 healthy controls from Sweden. A sliding window haplotype analysis was conducted using a logistic regression model.Thereafter, we performed sequencing to find candidate variants, finally to be tested in a nested case-control study. Results: Candidate loci/genes on ten chromosomal regions were suggested with odds ratios (ORs) between 1.71-3.62 and p-values &lt; 5x10-8 in the analysis. The regions suggested were 1q32.2, 3q29, 4q35.1, 4p15.31, 4q26, 8p23.1, 13q33.3, 13q13.3, 16q23.3 and 22q11.21. All regions, except one on 1q32.2, had protein coding genes, many already shown to be involved in cancer, such as ZDHHC19, SYNPO2, PCYT1A, MYO16, TXNRD2, COMT, and CDH13. Sequencing of 122 colorectal cancer patients with gastric- and prostate cancer in their families identified 10 candidate variants from six of the loci in the haplotype regions to finally be tested in a nested case-control study of similar colorectal cancer cases and controls. Conclusions: There was some support for an increased risk of colorectal-, gastric-, and/or prostate cancer in all the six loci tested. [Table: see text]
Is the optimal examined lymph node number for rectal cancer altered？
Authors: Xiaoyan Li, Ke Hu
Journal: International Journal of Surgery (2024)

Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, the People's Republic of China Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, the People's Republic of China. E-mail address: [email protected] (K. Hu). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Authors: Anniek Frederike Lubberding, Simon Veedfald, Jonathan Samuel Achter, Sarah Dalgas Nissen, Luca Soattin, Andrea Sorrentino, Estefania Torres Vega, Benedikt Linz, Caroline Harriet Eggert Eggertsen, John Mulvey, Signe Toräng, Sara Agnete Larsen, Anne Nissen, Lonnie Grove Petersen, Secil Erbil Bilir, Bo Hjorth Bentzen, Mette Marie Rosenkilde, Bolette Hartmann, Thomas Nikolaj Bang Lilleør, Saddiq Qazi, Christian Holdflod Møller, Jacob Tfelt-Hansen, Stefan Michael Sattler, Thomas Jespersen, Jens Juul Holst, Alicia Lundby
Journal: Cardiovascular Research (2024)

Abstract Aims Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity. Albeit cardiovascular outcomes generally improve, treatment with GLP-1 RAs is associated with increased heart rate, the mechanism of which is unclear. Methods and results We employed a large animal model, the female landrace pig, and used multiple in vivo and ex vivo approaches including pharmacological challenges, electrophysiology, and high-resolution mass spectrometry to explore how GLP-1 elicits an increase in heart rate. In anaesthetized pigs, neither cervical vagotomy, adrenergic blockers (alpha, beta, or combined alpha-beta blockade), ganglionic blockade (hexamethonium), nor inhibition of hyperpolarization-activated cyclic nucleotide–gated (HCN) channels (ivabradine) abolished the marked chronotropic effect of GLP-1. GLP-1 administration to isolated perfused pig hearts also increased heart rate, which was abolished by GLP-1 receptor blockade. Electrophysiological characterization of GLP-1 effects in vivo and in isolated perfused hearts localized electrical modulation to the atria and conduction system. In isolated sinus nodes, GLP-1 administration shortened the action potential cycle length of pacemaker cells and shifted the site of earliest activation. The effect was independent of HCN blockade. Collectively, these data support a direct effect of GLP-1 on GLP-1 receptors within the heart. Consistently, single nucleus RNA sequencing showed GLP-1 receptor expression in porcine pacemaker cells. Quantitative phosphoproteomics analyses of sinus node samples revealed that GLP-1 administration leads to phosphorylation changes of calcium cycling proteins of the sarcoplasmic reticulum, known to regulate heart rate. Conclusion GLP-1 has direct chronotropic effects on the heart mediated by GLP-1 receptors in pacemaker cells of the sinus node, inducing changes in action potential morphology and the leading pacemaker site through a calcium signalling response characterized by PKA-dependent phosphorylation of Ca2+ cycling proteins involved in pacemaking. Targeting the pacemaker calcium clock may be a strategy to lower heart rate in people treated with GLP-1 RAs.